Tarsus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Tarsus Pharmaceuticals has a total shareholder equity of $197.0M and total debt of $29.8M, which brings its debt-to-equity ratio to 15.1%. Its total assets and total liabilities are $265.5M and $68.5M respectively.
Key information
15.1%
Debt to equity ratio
US$29.82m
Debt
| Interest coverage ratio | n/a |
| Cash | US$227.44m |
| Equity | US$196.99m |
| Total liabilities | US$68.50m |
| Total assets | US$265.49m |
Recent financial health updates
Recent updates
Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
Mar 08Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic
Mar 03
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 01Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Nov 12What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates
Aug 16Tarsus files for FDA approval of TP-03 to treat mite infestation in eyelids
Sep 07Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues
May 13A Look At The Fair Value Of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Dec 07Financial Position Analysis
Short Term Liabilities: TARS's short term assets ($256.1M) exceed its short term liabilities ($36.9M).
Long Term Liabilities: TARS's short term assets ($256.1M) exceed its long term liabilities ($31.6M).
Debt to Equity History and Analysis
Debt Level: TARS has more cash than its total debt.
Reducing Debt: TARS's debt to equity ratio has increased from 0% to 15.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TARS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TARS has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 64.3% each year.